Jun 2026 (Q2 FY26) — Aug 6, 2026
Cytokinetics Q2 FY26 — Strong MYQORZO Launch Momentum and Expanded Aficamten Pipeline Opportunities
Read the full callCytokinetics (CYTK) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Cytokinetics earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 28.6 | −57.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -626.0 | −459.0 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -199 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Guidance
What management said, and what became of it
15 of 23 judged targets kept · 10 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Completion of enrollment in the adolescent cohort of CEDAR-HCM | Complete enrollment in the adolescent cohort of CEDAR-HCM in Q4 2026 | Dec 2025 | during the quarter, we completed enrollment in the adolescent cohort ahead of prior expectations | Achieved |
| Completion of patient enrollment in COMET-HF | Complete enrollment in COMET-HF in 2026 | Dec 2024 | not providing specific guidance on when we think it will complete enrollment, but it will be into the beginning of 2027 for sure | Missed |
| Full-year 2026 GAAP combined R&D and SG&A expense | $830 million to $870 million | Dec 2025 | We are updating full year 2026 GAAP combined R&D and SG&A expense to a range of $860 million to $890 million from the previous range of $830 million to $870 million. | Revised Down |
8 of CYTOKINETICS INC's 33 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 30 more targets are in the full ledger.
Claimed
- MYQORZO net product revenues reached $25.3 million in Q2 FY26, driven by robust demand.
- MYQORZO new-to-brand prescriptions in the CMI category accelerated by 15% in Q2 FY26.
- Over 700 unique healthcare providers in the U.S. have prescribed MYQORZO by end of Q2 FY26.
- MYQORZO achieved over 40% new-to-brand prescription exit share in the CMI category by end of Q2 FY26.
- Positive top-line results from ACACIA-HCM for aficamten in nHCM met both dual primary endpoints.
Qualified
- Net loss for Q2 FY26 was $198.8 million, or $1.50 per share, compared to $134.4 million or $1.12 per share in Q2 FY25.
- Licensing or milestone revenues were $0 in Q2 FY26, down from $64.4 million in Q2 FY25 due to prior year milestones.
- SG&A expenses increased to $104.4 million in Q2 FY26 from $65.7 million in Q2 FY25, primarily due to commercial launch costs.
Price
$61.95 −3.08% · −$1.97
Performance −1.4% 1Y
1Y: $62.8 on 15 Oct 2025 → $61.95. High $87.26 (29 Jun 2026), low $54.76 (22 Oct 2025).
- Previous close
- $63.92
- 52-week range
- $54.76 – $87.26
- One year
- +5.07%
Overview
- Symbol
- CYTK
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
15 of 23 judged targets kept · 10 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Completion of enrollment in the adolescent cohort of CEDAR-HCM | Complete enrollment in the adolescent cohort of CEDAR-HCM in Q4 2026 | Dec 2025 | during the quarter, we completed enrollment in the adolescent cohort ahead of prior expectations | Achieved |
| Completion of patient enrollment in COMET-HF | Complete enrollment in COMET-HF in 2026 | Dec 2024 | not providing specific guidance on when we think it will complete enrollment, but it will be into the beginning of 2027 for sure | Missed |
| Full-year 2026 GAAP combined R&D and SG&A expense | $830 million to $870 million | Dec 2025 | We are updating full year 2026 GAAP combined R&D and SG&A expense to a range of $860 million to $890 million from the previous range of $830 million to $870 million. | Revised Down |
Claimed
- MYQORZO net product revenues reached $25.3 million in Q2 FY26, driven by robust demand.
- MYQORZO new-to-brand prescriptions in the CMI category accelerated by 15% in Q2 FY26.
- Over 700 unique healthcare providers in the U.S. have prescribed MYQORZO by end of Q2 FY26.
- MYQORZO achieved over 40% new-to-brand prescription exit share in the CMI category by end of Q2 FY26.
- Positive top-line results from ACACIA-HCM for aficamten in nHCM met both dual primary endpoints.
Qualified
- Net loss for Q2 FY26 was $198.8 million, or $1.50 per share, compared to $134.4 million or $1.12 per share in Q2 FY25.
- Licensing or milestone revenues were $0 in Q2 FY26, down from $64.4 million in Q2 FY25 due to prior year milestones.
- SG&A expenses increased to $104.4 million in Q2 FY26 from $65.7 million in Q2 FY25, primarily due to commercial launch costs.
The full ledger
Open CYTOKINETICS INC’s full ledger
A free account opens 5 company ledgers a month. All 33 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — May 5, 2026
Cytokinetics Q1 FY26 — Strong MYQORZO Launch and Positive ACACIA-HCM Results
Read the full callDec 2025 (Q4 FY25) — Feb 24, 2026
Cytokinetics Q4 FY25 — Myqorzo Global Approvals and Commercial Launch Underway
Read the full callEvery analysed call
Cytokinetics earnings calls (CYTK)
Financials
What the filings say
Net profit, year on year: −48% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 17 | 2 | 67 | 2 | 18 | 19 | 29 |
| Operating profit | -141 | -139 | -156 | -112 | -167 | -178 | -184 | -179 |
| Operating margin | −30410.6% | −821.4% | −9856.3% | −167.0% | −8613.4% | −1004.6% | −948.7% | −626.0% |
| Other income | 17 | 15 | 14 | 13 | 10 | 11 | 11 | 14 |
| Interest | 9 | 9 | — | 11 | 11 | 14 | — | — |
| Net profit | -161 | -150 | -161 | -134 | -306 | -183 | -206 | -199 |
| EPS ($ per share) | -1.36 | — | -1.36 | -1.12 | -2.55 | — | -1.67 | -1.50 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -743 | -865 | -992 | -1,208 | -1,586 | -2,112 | -2,702 | -3,487 |
| Total liabilities | 185 | 301 | 420 | 597 | 1,123 | 1,211 | 1,537 | 2,084 |
| Fixed assets | 3 | 5 | 13 | 73 | 80 | 69 | 66 | 79 |
| Total assets | 211 | 290 | 534 | 841 | 1,015 | 824 | 1,402 | 1,425 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -101 | -91 | 9 | -143 | -300 | -414 | -396 | -510 |
| Cash from investing | 5 | -75 | -197 | -148 | -262 | 239 | -553 | 17 |
| Cash from financing | 13 | 160 | 234 | 320 | 516 | 221 | 931 | 524 |
| Net cash flow | -83 | -6 | 47 | 30 | -45 | 46 | -18 | 30 |
| Capital expenditure | -1 | -3 | -11 | -49 | -11 | -1 | -4 | -25 |
| Free cash flow | -102 | -94 | -2 | -191 | -311 | -416 | -400 | -535 |
CYTK operating KPIs by quarter
| KPI | Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|
| Prescribers MYQORZO | 275+In Q1, we saw strong demand with more than 275 unique HCPs prescribing MYQORZO with over 50% from the high-volume CMI writer segment.Source: earnings call transcript | 700+By the end of the quarter, more than 700 unique health care providers in the US have prescribed MYQORZO including approximately 300 physicians from the high-volume CMI writer segment.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Insider filings
208 filings between Oct 21, 2025 and Oct 12, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$51.97M
86 sales by 10 insiders
88% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 42
- Award — granted as compensation
- 67
- Option exercise — converted options into shares
- 9
- Tax withheld — shares kept back by the company to cover tax
Also filed: 4 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Blum Robert I | — | $17.46M | Oct 12, 2026 |
| Callos Andrew | — | $16.02M | Aug 31, 2026 |
| Lee Sung | — | $5.70M | Jul 1, 2026 |
| Malik Fady Ibraham | — | $4.75M | Oct 6, 2026 |
| Kaye Edward M. MD | — | $2.43M | Jun 1, 2026 |
| HENDERSON JOHN T | — | $2.08M | May 5, 2026 |
| WIERENGA WENDELL | — | $1.88M | May 5, 2026 |
| PARSHALL B LYNNE | — | $1.36M | Sep 1, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 12, 2026 | Blum Robert I President & CEO | Sale 10b5-1 plan | 7,500 | $471.6K |
| Oct 12, 2026 | Blum Robert I President & CEO | Option exercise 10b5-1 plan | 7,500 | $79.5K |
| Oct 6, 2026 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 plan | 3,500 | $27.3K |
| Oct 6, 2026 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 plan | 3,500 | $214.8K |
| Sep 28, 2026 | Blum Robert I President & CEO | Sale 10b5-1 plan | 7,500 | $490.9K |
| Sep 28, 2026 | Blum Robert I President & CEO | Option exercise 10b5-1 plan | 7,500 | $79.5K |
| Sep 22, 2026 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 plan | 3,500 | $27.3K |
| Sep 22, 2026 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 plan | 3,500 | $239.0K |
| Sep 15, 2026 | Blum Robert I President & CEO | Sale 10b5-1 plan | 97,926 | $6.79M |
| Sep 15, 2026 | Landry Robert E Director | Sale 10b5-1 plan | 1,000 | $72.1K |
| Sep 14, 2026 | Blum Robert I President & CEO | Sale 10b5-1 plan | 7,500 | $550.8K |
| Sep 14, 2026 | Blum Robert I President & CEO | Option exercise 10b5-1 plan | 7,500 | $79.5K |
| Sep 14, 2026 | Blum Robert I President & CEO | Gift 10b5-1 plan | 97,926 | $0 |
| Sep 14, 2026 | Blum Robert I President & CEO | Gift 10b5-1 plan | 97,926 | $0 |
| Sep 14, 2026 | Blum Robert I President & CEO | Gift 10b5-1 plan | 1,350 | $0 |
| Sep 11, 2026 | Landry Robert E Director | Sale 10b5-1 plan | 1,000 | $74.7K |
| Sep 8, 2026 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 plan | 3,500 | $264.1K |
| Sep 8, 2026 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 plan | 3,500 | $27.3K |
| Sep 1, 2026 | PARSHALL B LYNNE Director | Sale 10b5-1 plan | 5,000 | $357.4K |
| Aug 31, 2026 | Blum Robert I President & CEO | Sale 10b5-1 plan | 7,500 | $526.8K |
| Aug 31, 2026 | Callos Andrew EVP, Chief Commercial Officer | Option exercise 10b5-1 plan | 10,000 | $232.6K |
| Aug 31, 2026 | Blum Robert I President & CEO | Option exercise 10b5-1 plan | 7,500 | $79.5K |
| Aug 31, 2026 | Callos Andrew EVP, Chief Commercial Officer | Sale 10b5-1 plan | 10,000 | $702.4K |
| Aug 18, 2026 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 plan | 3,500 | $265.4K |
| Aug 18, 2026 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 plan | 3,500 | $27.3K |
| Aug 10, 2026 | Blum Robert I President & CEO | Option exercise 10b5-1 plan | 7,500 | $79.5K |
| Aug 10, 2026 | Blum Robert I President & CEO | Sale 10b5-1 plan | 7,500 | $575.7K |
| Jul 30, 2026 | Callos Andrew EVP, Chief Commercial Officer | Sale 10b5-1 plan | 14,000 | $1.12M |
| Jul 30, 2026 | Callos Andrew EVP, Chief Commercial Officer | Option exercise 10b5-1 plan | 14,000 | $325.6K |
| Jul 27, 2026 | Blum Robert I President & CEO | Sale 10b5-1 plan | 7,500 | $606.5K |
| Jul 27, 2026 | Blum Robert I President & CEO | Option exercise 10b5-1 plan | 7,500 | $79.5K |
| Jul 21, 2026 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 plan | 3,500 | $27.3K |
| Jul 21, 2026 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 plan | 3,500 | $282.1K |
| Jul 15, 2026 | Kaye Edward M. MD Director | Award | 151 | $12.5K |
| Jul 15, 2026 | HENDERSON JOHN T Director | Award | 272 | $22.5K |
| Jul 15, 2026 | Harrington Robert Arthur Director | Award | 151 | $12.5K |
| Jul 15, 2026 | Wysenski Nancy Director | Award | 75 | $6.2K |
| Jul 15, 2026 | WIERENGA WENDELL Director | Award | 75 | $6.2K |
| Jul 15, 2026 | Daly James M Director | Award | 151 | $12.5K |
| Jul 13, 2026 | Blum Robert I President & CEO | Option exercise 10b5-1 plan | 7,490 | $79.4K |
| Jul 13, 2026 | Blum Robert I President & CEO | Sale 10b5-1 plan | 10 | $820 |
| Jul 13, 2026 | Blum Robert I President & CEO | Sale 10b5-1 plan | 7,490 | $614.3K |
| Jul 7, 2026 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 plan | 3,500 | $303.2K |
| Jul 7, 2026 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 plan | 3,500 | $27.3K |
| Jul 1, 2026 | Lee Sung EVP, Chief Financial Officer | Option exercise 10b5-1 plan | 1,112 | $53.9K |
| Jul 1, 2026 | Lee Sung EVP, Chief Financial Officer | Sale 10b5-1 plan | 1,112 | $97.6K |
| Jul 1, 2026 | Blum Robert I President & CEO | Sale 10b5-1 plan | 7,500 | $636.9K |
| Jul 1, 2026 | Callos Andrew EVP, Chief Commercial Officer | Sale 10b5-1 plan | 15,000 | $1.29M |
| Jul 1, 2026 | Callos Andrew EVP, Chief Commercial Officer | Option exercise 10b5-1 plan | 15,000 | $348.9K |
| Jun 29, 2026 | Lee Sung EVP, Chief Financial Officer | Sale 10b5-1 plan | 3,134 | $266.4K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for CYTOKINETICS INC
Free account. Everything above stays public.
Write why you follow CYTOKINETICS INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading